Immunovant Stock Math Transform Price Common Logarithm

Methodology

Unless otherwise specified, financial data for Immunovant is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Immunovant (USA Stocks:IMVT) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Immunovant is covered by 17 analysts. 8 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Citigroup, UBS Investment Research, Oppenheimer & Co., Raymond James, Bank of America Securities, Wells Fargo Securities, Morgan Stanley, Evercore ISI, among others. Updates may occur throughout the day.

Immunovant Stock is Curated By:

Ellen Johnson · Member of Macroaxis Editorial Board